Mazorra, Z., Lavastida, A., Concha-Benavente, F., Valdés, A., Srivastava, R.M., García-Bates, T.M., et al. (2017) Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients. Frontiers in Pharmacology, 8, 382.
http://www.frontiersin.org
https://doi.org/10.3389/fphar.2017.00382

has been cited by the following article:

• TITLE: Specific Immunotherapy in Advanced Cervical-Uterine Cancer Using Humanized Monoclonal Antibody Nimotuzumab and CIMAvax-EGF® Therapeutic Vaccine

  AUTHORS: Raiza Ruiz-Lorente, Sayly Alfonso, Eduardo Santiesteban, Yamilka Sánchez, Kirenia Camacho, Erasmo Mendoza, Carmen Elena Viada, Ramón Ortiz, Ihosvannys Carreño, Mayelin Troche, Meylan Cepeda, Ana Rosa Vals, Leticia Cabrera, Annia Gorte, Delmis Batista, Milagros Domenech, Yanela Santiesteban, Yuliannis Santiesteban, Daymys Estevez, Jessica García-Viamontes, Conrado Ramos Mico, Mayra Ramos-Suzarte

  KEYWORDS: CIMAvax-EGF®, Nimotuzumab, Survival, Safety, Advanced Cervical Cancer

  JOURNAL NAME: Journal of Cancer Therapy, Vol.12 No.3, March 25, 2021

  ABSTRACT: Cervical uterine cancer represents the fourth most common malignant neoplasm worldwide in the female sex in terms of incidence, principally from epithelial origen. The high expression of EGFR in this tumor leads to the search for therapeutic alternatives. An Expanded Access Clinical Program was carried out in parallel groups, randomized, multicenter and prospective study, to evaluate the survival of patients with advanced cervical carcinoma, without therapeutic alternative, who would be treated with the therapeutic vaccine CIMAvax-EGF®, the humanized mAb nimotuzumab or the combination of both products, which targeted EGF and EGFR respectively. The patients were included between 2008 and 2010 with a more than five years follow-up. The results show that the serious adverse events related to the experimental treatments were 0.9%; 1.1% and 2.6% and a median ITT survival of 9.1, 23.5, and 16.3 months for CIMAvax-EGF®, nimotuzumab and the combination of both, respectively. Thus fulfilling the hypothesis of safety and efficacy proposed in the investigation was achieved. The three therapeutic regimens achieved overall survival rates greater than 35% at 60 months, encouraging results for advanced uterine cervical cancer. A phase III clinical trial is proposed to consolidate these results in a greater number of patients with nimotuzumab as study drug.